Momentous Prescribing Data and Outcomes Signals: An Independent Review

What "Prescribing Data" Actually Means for a Supplement Brand

Momentous is a supplement company, not a telehealth platform or compounding pharmacy. No prescribing data exists because the brand does not prescribe anything. That distinction matters clinically.

Dietary supplements sold in the United States are governed by the Dietary Supplement Health and Education Act (DSHEA) of 1994, which the FDA administers [1]. Under DSHEA, manufacturers do not need to demonstrate efficacy or safety before placing a product on the market. The FDA may act after the fact if a product is found to be adulterated or misbranded, but pre-market clinical trials are not required [1].

Why the Absence of Prescribing Data Is Expected

Because Momentous sells over-the-counter products, there is no prescriber-of-record, no prescription drug monitoring program entry, and no outcomes database tied to patient records. Comparing Momentous to a GLP-1 telehealth provider on "prescribing data" is a category error.

The clinically meaningful audit question is different: do the ingredients in Momentous products match doses and formulations shown to work in peer-reviewed trials? That question has a tractable answer.

DSHEA and Its Limitations for Consumers

The Federal Trade Commission and FDA both maintain guidance on supplement marketing claims [2]. A supplement label may not claim to diagnose, cure, treat, or prevent disease without becoming a drug by definition [1]. Momentous markets products with structure/function claims ("supports muscle recovery," "promotes focus"), which are permissible under DSHEA provided a disclaimer appears. The disclaimer requirement is codified at 21 CFR 101.93 [1].

Consumers relying on structure/function claims should understand that these claims do not require FDA review before they appear on a label. The FTC has brought enforcement actions against supplement companies for unsubstantiated performance claims, and those actions are publicly searchable at FTC.gov [2].

Creatine Monohydrate: The Ingredient With the Strongest Evidence Base

Creatine monohydrate is the ingredient most associated with Momentous in search and social contexts. The evidence for creatine monohydrate in athletic performance and muscle physiology is more developed than for almost any other legal supplement.

What the RCT Literature Shows

A 2017 position paper from the International Society of Sports Nutrition (ISSN) concluded that creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass [3]. That position statement reviewed over 500 peer-reviewed publications.

A meta-analysis published in the Journal of Strength and Conditioning Research (k=22 studies, N=651) found that creatine supplementation produced a mean 8% increase in 1-repetition maximum strength and a 14% increase in the number of repetitions performed at a given load compared with placebo [4]. Effect sizes were consistent across sex and training status.

Creatine's mechanism is well-characterized. Oral supplementation of 3 to 5 g/day raises intramuscular phosphocreatine stores by roughly 20%, accelerating ATP resynthesis during high-intensity, short-duration efforts [3]. This is not a contested pharmacological claim. It is replicated across independent laboratories.

Standard Dosing Protocols

The ISSN position paper describes two accepted protocols [3]:

• Loading: 20 g/day divided into four 5 g doses for 5 to 7 days, followed by 3 to 5 g/day maintenance.
• Non-loading: 3 to 5 g/day from the start, reaching the same intramuscular saturation after approximately 28 days.

Momentous markets a 5 g/day serving, which aligns with maintenance-phase dosing in the published literature. There is no proprietary dose advantage here; the effective dose is the same regardless of brand.

Creatine Safety Profile

Creatine monohydrate has one of the most thoroughly reviewed safety records of any supplement. A review covering over 30 years of use found no clinically significant adverse effects at standard doses in healthy adults [5]. Concerns about renal stress in healthy individuals are not supported by the controlled trial literature [5]. Persons with pre-existing kidney disease should consult a physician before use, per standard guidance.

Serum creatinine may rise slightly with supplementation because creatine is metabolized to creatinine. This is a laboratory artifact, not a marker of renal dysfunction [5]. Clinicians should be aware of this when interpreting metabolic panels in patients using creatine.

Third-Party Testing: What NSF and Informed Sport Certification Actually Means

Momentous claims NSF Certified for Sport and Informed Sport certification on select products. These are the two most widely recognized third-party testing programs for athletic supplements in North America and Europe.

NSF Certified for Sport

NSF International is an accredited, independent testing organization. NSF Certified for Sport verifies that a product contains what the label states, does not contain substances banned by major sports organizations (WADA, USADA, NCAA), and is manufactured in a facility that meets NSF/ANSI 173 dietary supplement Good Manufacturing Practice standards [6].

NSF publishes a searchable database of certified products at NSF.org. Clinicians and athletes can verify any claimed certification directly rather than relying on brand-side marketing copy. A product carrying the NSF Certified for Sport mark has undergone batch testing; a product merely claiming to be "third-party tested" without a named certifier has not necessarily undergone the same scrutiny.

Informed Sport

Informed Sport, operated by LGC Group, is the UK-based equivalent program recognized by most professional sports organizations internationally. It involves lot-by-lot testing for banned substances using anti-doping laboratory methods [7].

Both programs charge the manufacturer for testing and certification. Certification is product-specific and lot-specific. A certification on one SKU does not cover an adjacent, uncertified SKU from the same brand. This is a common consumer misunderstanding.

LegitScript Status

LegitScript is a verification and monitoring service primarily relevant to online pharmacies and telehealth prescribers. Momentous is not a pharmacy and is not expected to carry LegitScript certification. Its absence is not a negative signal for a supplement company in the same way it would be for a platform dispensing prescription medications [8].

BBB Standing and Consumer Complaints

The Better Business Bureau (BBB) provides accreditation and complaint records for businesses in North America. As of January 2025, Momentous does not hold BBB accreditation.

What BBB Non-Accreditation Means

BBB accreditation is voluntary and fee-based. Many legitimate businesses, including large publicly traded companies, are not BBB-accredited. Non-accreditation alone is not evidence of fraud or misconduct.

BBB profiles do record consumer complaints and company responses. Publicly available complaint patterns for supplement brands frequently involve billing disputes, subscription cancellation difficulty, and product efficacy disagreements. These categories of complaint are common across the supplement industry rather than being specific to any single brand.

Consumers can search the BBB database directly at BBB.org for the most current complaint volume and resolution rates.

FDA Warning Letters and Enforcement Actions

The FDA maintains a public database of warning letters sent to supplement companies [9]. A search of the FDA warning letter database as of the date of this review does not return enforcement correspondence directed at Momentous specifically. The absence of a warning letter is not a quality endorsement; many non-compliant products are never formally actioned. But an active warning letter would be a material negative signal, and clinicians should check this database periodically for brands their patients use [9].

Omega-3, Protein, and Other Momentous Products: Ingredient-Level Evidence

Beyond creatine, Momentous markets omega-3 fish oil, whey and plant protein, and cognitive support formulations. The evidence base varies substantially by ingredient.

Omega-3 Fatty Acids

Omega-3 supplementation with EPA and DHA has a large and mixed literature. The ASCEND trial (N=15,480, median follow-up 7.4 years) found no significant reduction in serious cardiovascular events with 1 g/day omega-3 supplementation in patients with diabetes [10]. By contrast, the REDUCE-IT trial (N=8,179) found that 4 g/day icosapentaenoic acid (Vascepa/icosapent ethyl) reduced major adverse cardiovascular events by 25% relative to placebo in patients with elevated triglycerides [11].

The dose difference matters clinically. Most consumer omega-3 supplements, including typical 1 g softgels, do not replicate the REDUCE-IT dose or formulation. The American Heart Association's 2019 advisory specifies that 4 g/day prescription omega-3 acids are indicated for triglyceride reduction, while lower OTC doses have less established cardiovascular benefit [12].

Whey Protein

Protein supplementation post-exercise supports muscle protein synthesis. A meta-analysis in the British Journal of Sports Medicine (k=49 studies, N=1,863) found that protein supplementation significantly increased gains in fat-free mass during resistance training (mean difference 0.3 kg, 95% CI 0.09 to 0.52 kg) [13]. The total daily protein intake mattered more than the specific supplement brand or timing in that analysis.

The Recommended Dietary Allowance for protein is 0.8 g/kg/day, but the ISSN position on protein suggests 1.4 to 2.0 g/kg/day for exercising individuals [14]. A whey protein product contributes to that total; its brand of origin does not change the amino acid profile in any meaningful way.

Signal Quality: What Outcomes Data Would Actually Require

Genuine outcomes signal generation for a supplement brand would require a specific infrastructure that OTC brands are not obligated to build. The framework below describes the minimum credible evidence standard that would allow a brand like Momentous to make outcomes-based claims:

Level 1 (Ingredient-referenced): The formulation matches doses used in published RCTs for the claimed outcome. Momentous creatine meets this standard.

Level 2 (Internal cohort data): The company tracks customer-reported outcomes against a control group with validated instruments (e.g., handgrip dynamometry, VO2max testing, PROMIS fatigue scale). No public evidence exists that Momentous operates a Level 2 program.

Level 3 (Prospective RCT on branded product): An independently registered, placebo-controlled trial testing the specific product formulation in a defined population. Brand-sponsored RCTs at this level are rare in the supplement industry and vulnerable to sponsorship bias unless pre-registered on ClinicalTrials.gov.

Level 4 (Post-market surveillance with adverse event reporting): A structured system capturing adverse events and submitting MedWatch reports to the FDA. DSHEA requires reporting of serious adverse events (21 CFR 111 Subpart P) [1]. The FDA MedWatch database is publicly searchable for serious adverse event reports by product [15].

Clinicians advising patients on supplement use should ask which level of evidence a brand is operating at. Most supplement brands, including Momentous, operate at Level 1 at best for most products.

Regulatory Context: State Boards and Scope

State medical boards and pharmacy boards regulate the prescribing and dispensing of prescription drugs. Momentous is not subject to state board oversight in any prescribing capacity because it sells no prescription products.

State attorney general offices have enforcement authority over deceptive trade practices, including misleading health claims. The FTC shares jurisdiction with the FDA over supplement advertising [2]. Athletes subject to WADA or USADA testing should use only NSF Certified for Sport or Informed Sport-certified products regardless of brand, because the supplement manufacturing environment carries inherent contamination risk [6].

The FDA's Current Good Manufacturing Practice regulations for dietary supplements (21 CFR Part 111) require identity, purity, strength, and composition testing, but enforcement gaps exist industry-wide [1]. Third-party certification programs like NSF exist partly to fill those gaps.

Practical Clinical Guidance

Patients asking about Momentous products should receive ingredient-level counseling rather than brand-level endorsement or dismissal. Creatine monohydrate at 3 to 5 g/day is supported by strong evidence for strength and power athletes. Clinicians should verify NSF or Informed Sport certification for any specific lot a patient intends to use by checking the certifier's database directly.

Patients using omega-3 supplements for cardiovascular risk reduction should understand that OTC doses below 4 g/day of EPA/DHA have not replicated the outcomes seen in the REDUCE-IT trial, and that prescription icosapent ethyl (Vascepa) is the formulation studied for that indication [11].

Clinicians should monitor serum creatinine for artifact elevation in patients using creatine, and should check the FDA warning letter database and MedWatch for any brands their patients use regularly [9][15].